Search

Your search keyword '"THERAPEUTIC use of antineoplastic agents"' showing total 4,388 results

Search Constraints

Start Over You searched for: Descriptor "THERAPEUTIC use of antineoplastic agents" Remove constraint Descriptor: "THERAPEUTIC use of antineoplastic agents"
4,388 results on '"THERAPEUTIC use of antineoplastic agents"'

Search Results

1. Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers.

2. Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer.

3. Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR‐mutated lung cancer and pulmonary tuberculosis: A case report.

4. Berberine inhibits the progression of breast cancer by regulating METTL3‐mediated m6A modification of FGF7 mRNA.

5. Fertility and Pregnancy-Related Issues in Young BRCA Carriers With Breast Cancer.

6. Predictive modeling and regression analysis of diverse sulfonamide compounds employed in cancer therapy.

7. Topical and Intralesional Immunotherapy for the Management of Basal Cell Carcinoma.

8. Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma.

9. Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission †

10. Therapeutic Targets in Advanced Penile Cancer: From Bench to Bedside.

11. Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation.

12. The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review.

13. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy.

14. N -Benzylated 5-Hydroxybenzothiophene-2-carboxamides as Multi-Targeted Clk/Dyrk Inhibitors and Potential Anticancer Agents.

15. Coupling Kinesin Spindle Protein and Aurora B Inhibition with Apoptosis Induction Enhances Oral Cancer Cell Killing.

16. Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC).

17. Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed.

18. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents.

19. Prospective, Observational Study of Aflibercept Use in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer: A Real-World Effectiveness Study.

20. Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.

21. Therapeutic Patterns and Clinical Outcomes in Limited Disease Small Cell Lung Cancer: A Decade of Analysis at a Tertiary Cancer Center.

22. Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases.

23. Impact of Tumor Shrinkage Pattern with Biweekly Triplet Gemcitabine+Cisplatin+S-1 Regimen for Biliary Tract Cancers: Implications for Neoadjuvant Therapy from the Data of KHBO1401 (KHBO1401-1A Study).

24. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis.

25. Inhibition of Wnt Signaling by Atovaquone Inhibits Gastric Cancer and Enhances Chemotherapy Effectiveness Through Activation of Casein Kinase 1α.

26. Protein kinase inhibitors in the management of cancer: therapeutic opportunities from natural compounds.

27. Successful switch to cisplatin-based chemotherapy in a patient with lung cancer who developed a carboplatin-induced hypersensitivity reaction.

28. Attitude of healthcare professionals toward the use of complementary and alternative medication during anti-cancer therapy.

29. Impact of concurrent medications on the outcome of immunotherapy in non‐small cell lung carcinoma.

30. Real‐world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non‐small cell lung cancer.

31. A Descriptive Study of Quality of Life Following Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

32. Recent and anticipated novel drug approvals for 2024.

33. Quantitative evaluation of the impact of relaxing eligibility criteria on the risk–benefit profile of drugs for lung cancer based on real‐world data.

34. Targeted Therapies in the Treatment of Mantle Cell Lymphoma.

35. Safety and Efficacy of High-Dose Chemotherapy with TreoMel 200 vs. TreoMel 140 in Acute Myeloid Leukemia Patients Undergoing Autologous Stem Cell Transplantation.

36. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma.

37. Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer—What Can We Learn from Breast Cancer?

38. Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review.

39. Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice.

40. Insights in Molecular Therapies for Hepatocellular Carcinoma.

41. Zebrafish Avatars: Toward Functional Precision Medicine in Low-Grade Serous Ovarian Cancer.

42. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.

43. Evorpacept-Induced Interference and Application of a Novel Mitigation Agent, Evo-NR, in Pretransfusion Testing.

44. Research Progress on CARM1 and its Relationship with Colorectal Cancer.

45. Radiotherapy and Anrotinib in Malignant Glomus Tumor of the Bladder: A Case Report and Literature Review.

46. Promising Therapeutic Targets in Kidney Renal Clear Cell Carcinoma: PLXNA1 and PLXNB3.

47. A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2− Breast Cancer: A Single-Institution Experience.

48. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.

49. Chemoradiotherapy Combined with Immunotherapy in Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety Outcomes.

50. Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis.

Catalog

Books, media, physical & digital resources